PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

By sjmartinez • November 27, 2024

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2416882121. doi: 10.1073/pnas.2416882121. Epub 2024 Nov 26. PMID: 39589879.

Tags: ASCL1, Endocrinology, Hematology/Oncology, Lung cancer, Oxidative phosphorylation, PGC-1a, prostate cancer, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Advancing biological understanding of cellular senescence with computational multiomics

Li S, Agudelo Garcia PA, Aliferis C, Becich MJ, Calyeca J, Cosgrove BD, Elisseeff J, Farzad N, Fertig EJ, Glass C, Gu L, Hu Q,[...]

Machine Learning to Diagnose Complications of Diabetes

Scheideman AF, Shao MM, Zelada H, Cuadros J, Foreman J, Sarder P, Ho C, Ejskjaer N, Fleischer J, Cichosz SL, Armstrong DG, Mathioudakis N, Wang[...]

Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy

Li Z, Freiberg S, Music ML, Gu L, Nacos S, Phillips JP, Hassan A, Shibbani K, Munir SS, Kumar VK, Halligan L, Michel ME, London[...]